These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37140011)

  • 1. Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis.
    Liu H; Yang CC; Ma YL; Yang YF; Yan LJ; Ding ZN; Xue JS; Yang LS; Yan YC; Dong ZR; Wang DX; Chen ZQ; Hong JG; Li T
    Immunotherapy; 2023 Jun; 15(9):669-678. PubMed ID: 37140011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
    Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
    Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.
    Pinter M; Jain RK; Duda DG
    JAMA Oncol; 2021 Jan; 7(1):113-123. PubMed ID: 33090190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Pinter M; Scheiner B; Peck-Radosavljevic M
    Gut; 2021 Jan; 70(1):204-214. PubMed ID: 32747413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
    Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
    Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
    Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
    Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bakouny Z; Assi T; El Rassy E; Nasr F
    J Clin Gastroenterol; 2019 Apr; 53(4):251-261. PubMed ID: 30575632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.
    Solimando AG; Susca N; Argentiero A; Brunetti O; Leone P; De Re V; Fasano R; Krebs M; Petracci E; Azzali I; Nanni O; Silvestris N; Vacca A; Racanelli V
    Clin Exp Med; 2022 Feb; 22(1):65-74. PubMed ID: 34146196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
    Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
    Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity.
    Wu Y; Lin H; You X; Guo T; Sun T; Xu H; Fu X
    Front Oncol; 2022; 12():764923. PubMed ID: 35356200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma.
    Liu T; Li Q; Lin Z; Wang P; Chen Y; Fu Y; Ding Z
    Int Immunopharmacol; 2021 Nov; 100():108128. PubMed ID: 34537483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
    J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.